Bendamustine hydrochloride NEW
| Price | $43 | $70 | $126 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Bendamustine hydrochloride | CAS No.: 3543-75-7 |
| Purity: 98.03% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Bendamustine hydrochloride |
| Description | Bendamustine hydrochloride (EP-3101) (IC50 of 50 μM) is an alkylating agent associated with DNA damage. |
| Cell Research | SU-DHL-1 and SU-DHL-9 cells are preincubated for 30 minutes with either 6 mM methoxyamine or 50 μM O6-benzylguanine, inhibitors of Ape-1 base excision repair enzyme, or alkylguanyl transferase enzyme, respectively. The cells are then exposed to various concentrations of Bendamustine for 72 hours. Cytotoxicity is evaluated by the MTT viability assay and an IC50 is determined as the drug concentration that inhibited by 50% the viability value of the untreated control. Analyses are done.(Only for Reference) |
| In vitro | Bendamustine causes more extensive and effective DNA single- and double-strand breaks than cyclophosphamide, Cisplatinum, or carmustine.Bendamustine inhibits mitotic assays and causes mitotic mega-mutations.Bendamustine regulates genes involved in apoptosis, DNA repair, and mitotic assays. Bendamustine had a very low teratogenic effect compared to an equimolar dose of Lomustine.26% of Bendamustine-treated MCF-7/ADR cells showed micronucleation compared to 6% of DMSO-treated cells. Bendamustine alone at concentrations ranging from 1 μg/mL to 50 μg/mL showed dose- and time-dependent effects with toxicity ranging from 30.4% to 94.8% observed after 48 hours. The LD50 of untreated and pretreated CLL cells was 7.3 or 4.4 μg/mL, respectively. Bendamustine treatment of SU-DHL-9 cells resulted in a 60% to 80% down-regulation of the mRNA expression of all three of these genes (polo-like kinase 1, Aurora kinase A, and cyclin B1). Bendamustine acts on non-Hodgkin's lymphocytes and uniquely regulates DNA repair pathways compared to other alkylating agents. Myeloid and breast cancer cells are resistant to Bendamustine, but HL-60 cells are moderately sensitive to Bendamustine. |
| In vivo | Bendamustine causes more extensive and effective DNA single- and double-strand breaks than cyclophosphamide, Cisplatinum, or carmustine.Bendamustine inhibits mitotic assays and causes mitotic mega-mutations.Bendamustine regulates genes involved in apoptosis, DNA repair, and mitotic assays. Bendamustine had a very low teratogenic effect compared to an equimolar dose of Lomustine.26% of Bendamustine-treated MCF-7/ADR cells showed micronucleation compared to 6% of DMSO-treated cells. Bendamustine alone at concentrations ranging from 1 μg/mL to 50 μg/mL showed dose- and time-dependent effects with toxicity ranging from 30.4% to 94.8% observed after 48 hours. The LD50 of untreated and pretreated CLL cells was 7.3 or 4.4 μg/mL, respectively. Bendamustine treatment of SU-DHL-9 cells resulted in a 60% to 80% down-regulation of the mRNA expression of all three of these genes (polo-like kinase 1, Aurora kinase A, and cyclin B1). Bendamustine acts on non-Hodgkin's lymphocytes and uniquely regulates DNA repair pathways compared to other alkylating agents. Myeloid and breast cancer cells are resistant to Bendamustine, but HL-60 cells are moderately sensitive to Bendamustine. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 14 mg/mL (35.5 mM) H2O : 2 mg/mL (5.06 mM) DMSO : 60 mg/mL (152.01 mM) |
| Keywords | EP 3101 | EP3101 | Bendamustine hydrochloride | antimetabolite | alkylating | purine | anticancer | inhibit | SDX 105 | Inhibitor | Bendamustine | DNA Alkylator/Crosslinker | Bendamustine Hydrochloride | Apoptosis | DNA | SDX105 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Guanidine hydrochloride | Metronidazole | Tributyrin | Thymidine |
| Related Compound Libraries | Bioactive Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $10.00/1kg |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-11-25 | |
| $43.00/25mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-09-05 | |
| $1.00/1Kg |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2024-07-19 | |
| $0.00/25KG |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2023-08-28 | |
| $0.00/1kg |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-10-14 | |
| $1.00/1KG |
Hubei Langyou International Trading Co., Ltd
|
2021-09-01 | ||
| $9.00/1KG |
Shijiazhuang tongyang Import and Export Co., LTD
|
2021-08-13 | ||
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-08-11 | ||
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-07-05 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY